KalVista Pharmaceuticals, Inc.
KALVNASDAQHealthcare● Active
$26.99
+$0.04(+0.15%)
Market Cap$1.4B
P/E Ratio—
52W High$26.99
52W Low$9.83
KalVista Pharmaceuticals, Inc. (KALV) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KALV · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2025-04 | 2024-04 | 2023-04 | 2022-04 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($164.29M) | ($183.44M) | ($126.64M) | ($92.91M) | ($82.34M) |
| Depreciation & Amort. | $1.45M | $0.94M | $0.82M | $0.72M | $0.74M |
| Stock-Based Comp. | $0.00M | $12.29M | $21.91M | $9.92M | $0.00M |
| Change in Working Capital | $0.95M | $15.04M | $15.17M | $7.41M | ($12.32M) |
| Net Cash from Operations | ($81.62M) | ($152.91M) | ($89.23M) | ($75.26M) | ($78.13M) |
| Investing Activities | |||||
| Capital Expenditure | ($1.71M) | ($0.43M) | ($0.44M) | ($1.20M) | ($0.93M) |
| Purchases of Investments | ($84.78M) | ($30.57M) | ($189.23M) | ($98.25M) | ($136.92M) |
| Sales of Investments | $105.36M | $122.52M | $104.95M | $140.86M | $195.71M |
| Net Cash from Investing | $18.68M | $91.02M | ($84.72M) | $41.41M | $57.86M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $160.72M | $98.04M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $162.64M | $159.73M | $150.71M | $58.12M | $1.58M |
| Free Cash Flow | |||||
| Free Cash Flow | ($83.33M) | ($153.34M) | ($89.67M) | ($76.46M) | ($79.06M) |
| FCF Margin %(computed) | -113.19% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more KalVista Pharmaceuticals, Inc. data
About KalVista Pharmaceuticals, Inc. (KALV) Cash Flow Statement
KalVista Pharmaceuticals, Inc. generated operating cash flow of ($0.08B) and free cash flow of ($0.08B) for 2025 — a FCF margin of -113.19%. Capital expenditure was ($0.00B).
Frequently asked questions
KALV · 4 questionsKalVista Pharmaceuticals, Inc. generated free cash flow of ($0.08B) for 2025, up 45.7% year-over-year.
KALV free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10